Trial intelligence / Profile preview

Carvedilol and Spironolactone for Heart Failure Prevention in Stage A/B

NCT02230891Phase 2

Key facts

Status
Completed
Start
Oct 2014
Primary completion
Dec 2020
Countries
1
Sponsor
VA Office of Research & Development
Modality
Small Molecules
Conditions
heart failure (HF)
01

Overview

Phase 2, randomised, open-label trial of carvedilol and spironolactone in heart failure (HF), sponsored by VA Office of Research & Development. Started Oct 2014; status: completed.

02

Design

Study design
RandomizedOpen-label
03

Who it enrols

Veterans aged >40 with Stage A/B heart failure, elevated hs-cTnT (>5 ng/L), and 10-year HF risk >5%.

04

Registry description

Despite advances in cardiovascular care, the occurrence of heart failure (HF) is steadily increasing. The increase in HF rates poses enormous challenges, as once an individual becomes symptomatic or requires hospitalization with HF, the prognosis remains poor. Therefore, prevention of HF is essential. HF prevention is a critical issue as HF risk factors that include common medical conditions such as hypertension and diabetes are also increasing. However, not everyone with these risk factors develops HF. Using novel blood tests, the investigators propose to identify and treat subjects at…

Beyond the preview

Go deeper on NCT02230891.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02230891.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call